Literature DB >> 10100327

Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis.

P W Swaan1, B C Koops, E E Moret, J J Tukker.   

Abstract

The present study was undertaken to examine the relationship between chemical structure (steric and electrostatic fields) and affinity for the small intestinal oligopeptide carrier (PepT1) using comparative molecular field analysis (CoMFA), a three-dimensional approach towards building quantitative structure-activity relationships. Various biological activity parameters (Kt, Jmax, Pc) and molecular descriptors (CoMFA fields, isobutylalcohol/water distribution coefficients) were examined. The resulting field map provides information on the geometry of the binding site cavity and the relative weights of various properties in different site pockets for each of the substrates considered. The results indicate that carrier permeability (Pc), calculated as the ratio of the half-maximal concentration (Kt) and the maximal carrier flux (Jmax), is sensitive to composition, size and hydrophobicity of the ligands. The best model obtained showed a high correlation between the carrier permeability (Pc) and the steric (76.3% contribution) and electrostatic (23.7% contribution) molecular fields with a cross-validated r2 (q2) of 0.754. The model fitted the experimental data with a correlation coefficient of 0.993 and a standard error of 0.041, while the regression line between experimental and calculated Pc had a slope of 0.994 with an intercept of 0.009. These results lead to a better understanding of the molecular requirements for optimal drug-carrier interactions with the intestinal peptide transporter and offers a useful visual aid for designing new potentially interesting structures with affinity for the oligopeptide transporter PepT1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10100327

Source DB:  PubMed          Journal:  Receptors Channels        ISSN: 1060-6823


  5 in total

1.  Membrane topology of human ASBT (SLC10A2) determined by dual label epitope insertion scanning mutagenesis. New evidence for seven transmembrane domains.

Authors:  Antara Banerjee; Peter W Swaan
Journal:  Biochemistry       Date:  2006-01-24       Impact factor: 3.162

2.  In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.

Authors:  Sean Ekins; Jeffrey S Johnston; Praveen Bahadduri; Vanessa M D'Souza; Abhijit Ray; Cheng Chang; Peter W Swaan
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

3.  Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide.

Authors:  S Ramanathan; S Pooyan; S Stein; P D Prasad; J Wang; M J Leibowitz; V Ganapathy; P J Sinko
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

4.  Development of a QSAR model for binding of tripeptides and tripeptidomimetics to the human intestinal di-/tripeptide transporter hPEPT1.

Authors:  Rikke Andersen; Flemming Steen Jørgensen; Lars Olsen; Jon Våbenø; Karina Thorn; Carsten Uhd Nielsen; Bente Steffansen
Journal:  Pharm Res       Date:  2006-02-26       Impact factor: 4.200

5.  A charge pair interaction between Arg282 in transmembrane segment 7 and Asp341 in transmembrane segment 8 of hPepT1.

Authors:  Ashutosh A Kulkarni; Daryl L Davies; Jennifer S Links; Leena N Patel; Vincent H L Lee; Ian S Haworth
Journal:  Pharm Res       Date:  2006-09-29       Impact factor: 4.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.